Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.…
Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
Relmada Therapeutics (NASDAQ: RLMD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 17 employees.
The shares were at 2.620 USD on 20 November 2026, roughly unchanged over 52 weeks. Its 52-week range is 2.420 USD to 8.000 USD: the price is 67.3% below the high and 8.3% above the low.
Its market capitalisation is 279.54M USD.
Relmada Therapeutics reports return on equity of -66.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 202.12M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.